Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.54USD
17 Jan 2018
Change (% chg)

$-0.08 (-12.92%)
Prev Close
$0.62
Open
$0.63
Day's High
$0.65
Day's Low
$0.52
Volume
3,350,963
Avg. Vol
582,780
52-wk High
$0.93
52-wk Low
$0.30

Chart for

About

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development... (more)
No analyst recommendations are available for .

Overall

Beta: -0.55
Market Cap(Mil.): $19.75
Shares Outstanding(Mil.): 31.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 203.19 16.42
EPS (TTM): -- -- --
ROI: -- -7.35 33.31
ROE: -- -29.01 17.56

BRIEF-Hemispherx Enters Sale/Leaseback Agreement For NJ Development And Production Facility

* HEMISPHERX ENTERS INTO SALE/LEASEBACK AGREEMENT FOR NJ DEVELOPMENT AND PRODUCTION FACILITY

8:39am EST

BRIEF-Hemispherx Biopharma posts Q3 ‍net loss $1.3 mln vs $2.9 mln last year

* Hemispherx Biopharma announces corporate progress and financial results for the nine months ended September 30, 2017

Nov 15 2017

BRIEF-Hemispherx Biopharma says files for resale of 5.4 mln shares of common stock, offered for sale by selling stockholders

* Hemispherx Biopharma - files for resale of of 5.4 million shares of common stock, offered for sale by selling stockholders - SEC Filing‍​ Source text: (http://bit.ly/2yegQEW) Further company coverage:

Sep 29 2017

BRIEF-Hemispherx Biopharma Co's board has reviewed financial condition of company and anticipated needs of company to pursue its goals

* Co's board has reviewed financial condition of company and anticipated needs of company to pursue its goals

Aug 29 2017

BRIEF-Hemispherx Biopharma announces corporate progress and financial results for the 6 months ended June 30 '17

* Hemispherx Biopharma announces corporate progress and financial results for the six months ended June 30, 2017

Aug 15 2017

BRIEF-Hemispherx Biopharma updates on study of Ampligen

* Hemispherx human safety study of intranasal Ampligen with influenza vaccine shows Ampligen was generally well-tolerated ‍​

Aug 14 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.24 -0.32
Pfizer Inc. (PFE.N) $37.18 +0.58
Merck & Co., Inc. (MRK.N) $62.03 -0.04
GlaxoSmithKline plc (GSK.L) 1,359.20 +4.20
AstraZeneca plc (AZN.L) 4,990.50 -58.50
Baxter International Inc (BAX.N) $68.20 +0.53
MediGene AG (MDG1k.DE) €13.60 +0.41

Earnings vs. Estimates